Medical/Pharmaceuticals
NUS researchers develop revolutionary technology to unravel complex protein interactions that could transform cancer diagnostics
Scalable and adaptable, TETRIS captures the diversity of protein interactions
on site to inform accurate cancer diagnoses, enabling the personalisation of
ensuing treatments.
SINGAPORE, Sept. 30, 2024 /PRNewswire/ -- A team of researchers from the
National University of Singapore's
2024-09-30 15:51
2038
Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeti...
2024-09-30 15:00
1810
IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ -- OnSeptember 23, in Rio de Janeiro, on the eve of the International Myeloma Society (IMS) Annual Meeting, Dr.Yongke Zhang, Chief Scientific Officer of IASO Biotherapeutics (IASO Bio), along with leading Chinese onco-h...
2024-09-30 13:48
1777
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
HONG KONG, Sept. 30, 2024 /PRNewswire/ -- September 30, 2024, Akeso (9926. HK) announced that its internally developed PD-1/CTLA-4 bispecific antibody, cadonilimab, has received approval from the National Medical Products Administration (NMPA) for a new indication: cadonilimab in combination with...
2024-09-30 13:42
1664
Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer
* Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of$850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire...
2024-09-30 13:00
1728
SeromYx Systems and ACROBiosystems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies
NEWARK, Del., Sept. 29, 2024 /PRNewswire/ -- SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, an innovative provider for life science solutions and tools, are excited to announce the release of their joint study on the comprehensive functional profiling of approv...
2024-09-29 21:00
2198
IASO Bio Presented Comparative Clinical Outcomes on the Optimal Lymphodepletion Prior to Infution of Equecabtagene Autoleucel（FucasoTM）in Patients with Relapsed Refractory Multiple Myeloma at 2024 IMS Annual Meeting
SHANGHAI and NANJING, China and SAN JOSE, Calif, Sept. 29, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentati...
2024-09-29 21:00
2919
New Beginnings, New Journey | Sanyou Opening of New 10,000-sqm Facility, Ushering in a New Era of Innovation for Bio Drugs
SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Sanyou Bio recently celebrated a prestigious move into its new 10,000-square-meter R&D building atShanghai headquarters. This is not just a change in physical location, but a qualitative leap in the company infrastructure. It marks a solid step forward for...
2024-09-28 20:00
4434
111, Inc. Announces Receipt of Notification from Nasdaq
SHANGHAI, Sept. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced it has received a...
2024-09-28 05:00
3737
Concord Medical Reports Financial Results for the First Half of 2024
BEIJING, Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced its unaudited consolidated financial results for t...
2024-09-27 19:00
4872
IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentat...
2024-09-27 15:41
1814
Datasea Announces Fiscal Year 2024 Financial Results with Revenue 6.6x that of 2023 Primarily due to Growth of its 5G AI Business
The Total Value of 5G-AI Contracts Currently in Process Exceeds $100 MM BEIJING, Sept. 26, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based digital technology company focused on innovative high-tech intelligent acoustics and 5G AI multimodal digital t...
2024-09-26 21:45
4648
Breakthrough Therapy Designation (BTD) for BioCity's SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria
SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 has been granted the Breakthrough Therapy Designation (BTD) by National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN...
2024-09-26 15:10
8663
Mediwhale Secures $12 Million in Series A2 Funding to Drive Global Leadership in Cardiovascular and Metabolic Disease Management
SEOUL, South Korea, Sept. 25, 2024 /PRNewswire/ -- Mediwhale
2024-09-26 02:00
2886
The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDA
CHONGQING, China, Sept. 25, 2024 /PRNewswire/ -- MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned subsidiary, Claruvis Pharmaceutical Co., has received approval from the U.S. Food and Drug A...
2024-09-25 21:18
2344
Flat Medical Strengthens Market Leadership with Acquisition of InjeQ Assets, Including FDA-Designated Breakthrough Device IQ-Tip®
TAIPEI, Sept. 25, 2024 /PRNewswire/ -- Flat Medical, a leading innovator in medical technology, today announced its acquisition of key assets from InjeQ, including the FDA-designated breakthrough device, IQ-Tip®. This strategic move bolsters Flat Medical's leadership position in the medical devic...
2024-09-25 20:00
2193
Samsung Biologics launches development platforms for enhanced therapeutic efficacy
* Samsung Biologics showcases new innovative development platforms – S-AfuCHO TM and S-OptiChargeTM – at BioProcess International 2024 * New technology platforms to proactively address evolving industry trends and enable high-quality development INCHEON, South Korea, Sept. 25, 2024 /PRNewswire...
2024-09-25 19:00
1948
XtalPi Launches Computational Chemistry Software for Drug Discovery: XMolGen and XFEP
BOSTON and SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- Today, XtalPi announced the official launch of XFEP and XMolGen, two proprietary software products designed to accelerate and enhance the efficiency of drug discovery. Upon this launch, XtalPi will offer commercial licenses with flexible terms f...
2024-09-24 21:00
4178
LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners
SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio" or the "Company"), a Phase III-stage biotech company focused on the R&D of innovative antibody and fusion protein drugs for allergies and complement-mediated diseases, announced the completion of its Series B2 ...
2024-09-24 21:00
2355
Noul Demonstrates 'Expert-Level' AI Diagnostic Performance in Europe… Results from Spain's Carlos III Health Institute
* Study of 329 Patients in Europe Shows Superior Performance Compared to Microscopic Diagnosis * Sensitivity: 94.4%, Specificity: 97.2%, Agreement Rate: 92% YONGIN, South Korea, Sept. 24, 2024 /PRNewswire/ -- Noul Co., Ltd. (CEO: David Lim, hereafter referred to as "Noul") has proven the expe...
2024-09-24 21:00
1787
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Multi-Award Winning Phuket Marriott Resort & Spa, Merlin Beach: Voted Top 3 Best Family Resort
[Picked up by 283 media titles]
2026-01-30 08:00
True 1000Hz Powerhouse: PHILIPS EVNIA Unleashes the World's First 1000Hz Dual-Mode Gaming Monitor 27M2N5500XD
[Picked up by 282 media titles]
2026-01-29 18:03
